Whitehawk Expands ADC Pipeline with Option for 5 New Programs
Whitehawk Therapeutics announced an expansion of its antibody drug conjugate (ADC) pipeline through a new option agreement with Hangzhou DAC Biotechnology. This agreement provides access to the CPT113 linker-payload for up to five additional ADC programs, with Whitehawk retaining global rights and full program control. The company expects to submit Investigational New Drug (IND) applications for multiple new programs within the next 12-24 months. The CPT113 linker-payload technology received external validation from Hangzhou DAC's DXC006 data presented at ASCO and Johnson & Johnson's JNJ-95437446 preclinical findings. Whitehawk's existing clinical programs, HWK-007 and HWK-016, are currently enrolling patients in Phase 1 dose-escalation trials, with data anticipated in the first half of 2027.
Key Highlights
- Whitehawk Therapeutics entered an option agreement with Hangzhou DAC for access to CPT113 linker-payload for up to five additional ADC programs.
- Whitehawk retains global rights and full program control for the new ADC programs.
- Company anticipates submitting Investigational New Drug (IND) applications for multiple new programs over the next 12-24 months.
- Hangzhou DAC presented data at ASCO for DXC006, a CD56-directed ADC utilizing CPT113, showing clinical activity and favorable safety.
- Johnson & Johnson disclosed preclinical findings for JNJ-95437446, an EGFR/MET ADC also using CPT113, supporting its Phase 1 development.
- Whitehawk's HWK-007 completed its first dose cohort at 2 mg/kg and is enrolling the second at 4 mg/kg.
- HWK-016 is enrolling its first dose cohort at 2.5 mg/kg for advanced ovarian and endometrial cancers.
- Phase 1 data for HWK-007 and HWK-016 are expected in the first half of 2027.
Price Impact
More from WHWK